Renaissance Technologies LLC purchased a new position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 11,000 shares of the company’s stock, valued at approximately $56,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allegheny Financial Group LTD bought a new stake in Lifecore Biomedical during the 2nd quarter worth about $52,000. SG Americas Securities LLC bought a new stake in shares of Lifecore Biomedical in the 1st quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Lifecore Biomedical in the 1st quarter valued at about $58,000. Oppenheimer Asset Management Inc. raised its holdings in shares of Lifecore Biomedical by 79.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 43,001 shares of the company’s stock valued at $228,000 after purchasing an additional 19,094 shares during the period. Finally, Boston Partners bought a new stake in shares of Lifecore Biomedical in the 1st quarter valued at about $104,000. 83.36% of the stock is owned by institutional investors.
Lifecore Biomedical Stock Up 0.2 %
Shares of LFCR opened at $4.63 on Tuesday. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $8.90. The firm has a market cap of $140.39 million, a P/E ratio of -1.38 and a beta of 0.95. The firm’s 50-day simple moving average is $5.03 and its 200 day simple moving average is $5.50. The company has a debt-to-equity ratio of 12.90, a quick ratio of 1.06 and a current ratio of 1.83.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on LFCR shares. Craig Hallum started coverage on shares of Lifecore Biomedical in a report on Thursday, September 5th. They issued a “buy” rating and a $8.00 target price on the stock. Barrington Research cut shares of Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 28th.
Get Our Latest Report on Lifecore Biomedical
Insiders Place Their Bets
In other Lifecore Biomedical news, major shareholder Wynnefield Partners Small Cap bought 122,930 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were purchased at an average price of $4.10 per share, for a total transaction of $504,013.00. Following the transaction, the insider now directly owns 2,095,783 shares in the company, valued at approximately $8,592,710.30. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 14.61% of the company’s stock.
Lifecore Biomedical Profile
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
Featured Stories
- Five stocks we like better than Lifecore Biomedical
- Best Aerospace Stocks Investing
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Breakout Stocks: What They Are and How to Identify Them
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.